Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025
About [ 212 Pb]VMT-α-NET
Perspective designed [ 212 Pb]VMT-α-NET to target and deliver 212 Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [ 212 Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212 Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET) and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product candidate finishing facilities, enabled by its proprietary 212 Pb generator, to deliver patient-ready product candidates for clinical trials and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's plans and the expected timing for the release of additional data from its clinical programs; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212 Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting moieties provide the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212 Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact.
The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Codex Labs to Exhibit at The Society for Pediatric Dermatology's 50th Annual Meeting
Seattle, Wash. - July 22nd, 2025 - Codex Labs, a biotech skincare company focused on microbiome-friendly solutions, is honored to participate in The Society for Pediatric Dermatology's (SPD) 50th Annual Meeting. Taking place from July 23rd to 26th at The Westin Seattle, the event will celebrate five decades of advancing pediatric dermatology through education, research, and collaboration. "Codex Labs is delighted to be attending The Society for Pediatric Dermatology's 50th Annual Meeting and presenting a novel plant-based biotech eczema lotion and cleanser for children as young as 3 weeks old,' says founder and CEO Dr. Barbara Paldus. 'We believe that these new topicals, when combined and targeted with pre- and probiotics, will usher in a future of highly effective, steroid-free alternatives for the management of pediatric atopic dermatitis." The SPD comprises over 1,800 members worldwide, including pediatricians, dermatologists, pediatric dermatologists, and other healthcare professionals. At this year's milestone 50th SPD Annual Meeting, Codex Labs will be one of many organizations gathering to support the advancement of pediatric dermatology. The SPD's 50th Annual Meeting will take place over four days and feature networking opportunities, support group discussions, lecture sessions, companies and exhibitors showcasing their products, and organizations dedicated to pediatric dermatology research and advancement. Some key topics highlighted at this year's meeting include infections, medications and therapies, psoriasis and inflammatory skin conditions, tumors and neoplasms, vascular lesions, and more. Codex Labs will be attending this year's 50th Annual Meeting and sponsoring the Early Career Networking Reception on Wednesday, July 23rd at 6:00 pm. This event is for medical doctors completing a fellowship or those out of training for five years or less, where they can share experiences and connect with other young dermatologists. Dr. Jessica Maloh, Naturopathic Doctor and Head of Naturopathic Medicine at Codex Labs, will be attending the event and presenting a research poster that highlights the use of oral probiotics as adjunctive interventions for acne. 'Acne is one of the most common skin conditions affecting adolescents, often impacting not only the skin, but also self-esteem and quality of life,' says Dr. Maloh. 'At the SPD, I'm excited to share a summary of the research on the adjunctive use of oral probiotics in acne management- an intervention that may complement conventional dermatologic treatments like antibiotics and oral isotretinoin. Integrative strategies like this have been found to enhance acne treatment efficacy while also supporting the gut microbiome.' Codex Labs is honored to participate in the 50th Annual Meeting and looks forward to showcasing its products and findings. Dr. Maloh invites guests to the Networking Reception and to visit her team's presentation to learn more about their skincare breakthroughs and the latest in integrative dermatology research. Event Details: Location: The Westin Seattle, located at 1900 5th Ave, Seattle, WA 98101. For more information about Codex Labs and its products, please visit If you are interested in learning more about Codex Labs' participation in The SPD's 50th Annual Meeting, please contact About Codex Labs: Based in Silicon Valley and led by scientist Dr. Barb Paldus, Codex Labs is committed to creating highly effective, clinically proven, microbiome-supporting skin-gut-brain-biome solutions that contain potent, biotech-derived plant-based actives. Codex Labs' products focus on restoring/protecting the skin barrier, managing inflammation, and addressing skin conditions associated with aging, acne, eczema, and psoriasis. The brand has been heralded by integrative dermatologists and naturopathic doctors for creating the next generation of effective, vegan, cruelty-free, and sustainable plant-based solutions.
Globe and Mail
8 hours ago
- Globe and Mail
Is QuantumScape Stock a Buy Now?
Key Points QuantumScape's solid-state lithium-metal battery technology aims to achieve higher energy density, faster charging, and improved safety compared to traditional lithium-ion batteries. The company has partnered with PowerCo, Volkswagen Group's battery manufacturing arm, to produce its technology and support a capital-light business model. Analysts predict that meaningful revenue won't materialize until 2027, with a surge forecast for 2028. 10 stocks we like better than QuantumScape › QuantumScape (NYSE: QS) is leading the charge to revolutionize energy storage with its innovative solid-state lithium-metal battery technology for electric vehicles and other applications. Its cutting-edge battery technology promises higher energy density and faster charging times, while also significantly improving safety compared to traditional lithium-ion batteries. The company has made headlines recently as its battery technology progresses, and the stock has surged 265% from its 52-week low. Here's what investors need to know about QuantumScape's investment prospects and what to expect from the company over the next several years. QuantumScape's battery technology ambitions Last year, QuantumScape partnered with PowerCo, the battery manufacturing arm of the Volkswagen Group. Volkswagen has been a significant investor in QuantumScape since 2012, committing around $380 million, and is the company's largest shareholder. QuantumScape's collaboration with PowerCo looks to advance its QSE-5 technology platform, with the goal of scaling up production at PowerCo's facilities. PowerCo is the "anchor customer" in QuantumScape's expanding technology ecosystem, as the company aims to develop a capital-light licensing model and expand its partnerships with customers worldwide. Instead of incurring heavy manufacturing investments, QuantumScape would license its technology to these partners, reducing its exposure to manufacturing risks and capital demands. QuantumScape is focused on broadening its range of potential licensing agreements with other automotive manufacturers. It also aims to strengthen its relationships with technology partners and key players across the battery value chain. This recent news sent the stock soaring One of QuantumScape's primary goals coming into 2025 was to bring the Cobra separator process into baseline production. Cobra represents a "step-change innovation in ceramics processing" designed to enable a significant improvement in separator productivity. This new process offers a 25 times improvement in heat treatment speed and requires only a fraction of the physical space per film start (compared to its prior-generation Raptor process). In June, the company announced that its Cobra separator process had reached baseline production, a key step toward commercializing its batteries. The successful baselining of Cobra is crucial for enabling higher-volume B1 sample production of their QSE-5 cells, which will be used in a launch program designed to showcase them, with field testing scheduled to commence in 2026. Since the announcement, the stock has surged 190%. Be mindful of the timeline and its finances One thing investors should be aware of regarding QuantumScape is that it is a company in its early growth stage. The company has not generated any revenue to date and continues to incur losses as it spends heavily on research and development. QuantumScape posted an operating loss of $123.6 million in the first quarter and expects to incur significant expenses and ongoing losses into the future. Capital expenditures in the first quarter of 2025 were $5.8 million, primarily supporting equipment and facilities for higher-volume QSE-5 B1 sample production using the Cobra separator process. The company's full-year capital expenditure guidance for 2025 is between $45 million and $75 million. QuantumScape reported $860.3 million in cash and equivalents at the end of the first quarter and anticipates this cash runway is enough to extend into 2028. This runway has expanded since it announced its licensing agreement with PowerCo, which is expected to lower costs and capital requirements compared to previous joint venture arrangements. Is QuantumScape a buy today? I'm excited about the potential of QuantumScape's groundbreaking battery technology, which has the potential to transform energy storage in the future. However, the company is still in the early stages of development and testing, and will continue to incur losses as it brings its vision to life. Analysts have noted that we should not expect meaningful revenue from QuantumScape until 2027, with projections of $51.6 million that year, followed by a significant leap to $265 million in 2028. Until then, we're looking at a story-driven stock that will attract attention but may not offer as much upside from here, especially given its recent surge. Should you invest $1,000 in QuantumScape right now? Before you buy stock in QuantumScape, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and QuantumScape wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
Winnipeg Free Press
21 hours ago
- Winnipeg Free Press
Allianz Life confirms data breach affecting majority of 1.4M US customers
MINNEAPOLIS (AP) — Hackers gained access to personal data on the majority of the 1.4 million customers of Allianz Life Insurance Company of North America, the company confirmed Saturday. Minneapolis-based Allianz Life, a subsidiary of Munich, Germany-based Allianz SE, said the data breach happened on July 16 when a 'malicious threat actor' gained access to a third-party, cloud-based system used by the company. 'The threat actor was able to obtain personally identifiable data related to the majority of Allianz Life's customers, financial professionals, and select Allianz Life employees, using a social engineering technique,' Allianz Life said in a statement. 'We took immediate action to contain and mitigate the issue and notified the FBI.' The company said its own systems were not accessed, just the third-party's platform. Allianz Life said its investigation is ongoing and that the company has begun reaching out to the impacted individuals. It said the incident involves only Allianz Life in the U.S., not other Allianz corporate entities. In the case of data breaches, a 'social engineering technique' usually involves using trickery to gain access. Spokesman Brett Weinberg said he couldn't provide details because they are still investigating. Allianz Life also reported the breach to multiple other authorities, including the Maine Attorney General's Office. A filing on the agency's website said the company discovered the breach the day after it happened, and that it will be offering those affected 24 months of identity theft protection and credit monitoring. Allianz Life was known as North American Life and Casualty until it was acquired by German conglomerate Allianz SE in 1979 and changed its name to Allianz Life Insurance Company of North America. It has nearly 2,000 employees in U.S., with the majority working in Minnesota, according to its website. It is one of five North American subsidiaries of the Munich-based global financial services group Allianz SE, which says it serves more than 125 million customers worldwide.
